CLINICAL LETTER

Painless idiopathic neuralgic amyotrophy after COVID-19 vaccination: A case report

On December 11, 2020, the Food and Drug Administration issued an emergency use authorization of the Pfizer-BioNtech COVID-19 vaccine for coronavirus disease 2019 (COVID-19) infection prevention, consisting of two intramuscularly administered doses 21 days apart. Large-scale placebo-controlled studies showed a 95% efficacy for COVID-19 infection prevention, with injection-site pain, fatigue, and headaches being commonly reported adverse events. Although idiopathic neuralgic amyotrophy (INA) has been reported after COVID-19 infection, there are currently no published cases of INA occurring after COVID-19 vaccination.

A 35-year-old left-hand dominant woman presented with new-onset painless left-arm weakness, numbness, and paresthesias 9 days after receiving the Pfizer-BioNtech COVID-19 vaccine in the right deltoid. She had no history of neurologic diseases or allergies and denied recent trauma or infection. A detailed physical examination showed left upper extremity decreased antigravity strength in the deltoid, supraspinatus, biceps brachii, triceps brachii, extensor carpi radialis, extensor digitorum communis, extensor indicis proprius, flexor digitorum superficialis, and flexor digitorum profundus. Left-arm light touch sensation was decreased in the lateral antebrachial cutaneous (LAC), radial, and median nerve distributions. Hyporeflexia of the left biceps, brachioradialis, and triceps deep-tendon reflexes was present. Normal strength, sensation, and reflexes were present in the right upper extremity, without increased tone, fasciculations, or atrophy. She exhibited left medial scapular winging, with negative provocative tests for radiculopathy, musculoskeletal shoulder pathology, and peripheral nerve entrapment.

Cervical spine computed tomography showed mild degenerative changes without foraminal narrowing. She was started on high-dose prednisone after neurology and physiatry evaluations, with paresthesias improvement and weakness stabilization within 1 week of medication initiation. Serologic evaluation including C-reactive protein, erythrocyte sedimentation rate, antinuclear antibody, rheumatoid factor, Lyme antibodies, and angiotensin-converting enzyme was negative. COVID-19 IgG and IgM antibodies were detected.

The patient was reevaluated 6 weeks after symptom onset with significant strength improvement and resolved numbness and paresthesias. She underwent electrodiagnostic evaluation showing an axonal and demyelinating brachial plexopathy, primarily involving the upper trunk (Table 1). Nerve conduction studies were normal, except for decreased amplitude, prolonged latency, and decreased conduction velocity of the left LAC sensory nerve action potential. Peripheral nerves with C5-C6 root contributions showed neuropathic changes and active denervation, including dorsal scapular, suprascapular, musculocutaneous, axillary, and radial nerves. This supported a diagnosis of post-vaccination INA and was reported through the Vaccine Adverse Event Reporting System (VAERS).

INA, also known as Parsonage-Turner syndrome, is an uncommon peripheral nerve disorder characterized by the rapid onset of upper extremity pain followed by weakness, atrophy, and sensory disturbances. Although INA classically presents with severe upper extremity or neck pain, painless INA has been described with an identical disease course, as seen in the presented case. INA has a reported incidence of 1.64/100,000 individuals, although the actual incidence is thought to be 20-30/100,000 because of misdiagnosis and decreased clinician recognition. An inciting event frequently proceeds symptom onset by 3-14 days, including trauma, infection, autoimmune disease, strenuous exercise, radiation, and vaccination. Recent immunization is a known risk factor, reported in about 15% of patients who develop INA. Although the pathophysiology of INA is poorly understood, an immune-mediated inflammatory reaction against the brachial plexus nerve fibers in a genetically predisposed individual is the currently accepted cause.

INA can be misdiagnosed as cervical radiculopathy, spinal cord compression, adhesive capsulitis, rotator cuff impingement, labral tear, glenohumeral osteoarthritis, malignancy, and amyotrophic lateral sclerosis.

Although INA is primarily a clinical diagnosis, electrodiagnostic evaluation can support the diagnosis and exclude other etiologies. Electrodiagnostic studies can show patchy damage to any nerve within the brachial plexus. Upper trunk involvement is most common, with suprascapular, long thoracic, axillary, musculocutaneous, LAC, and radial peripheral nerve involvement, as seen in this case. Electrodiagnostic abnormalities are usually not present until 3 weeks after symptom onset. Overall, patients with INA experience 80%-90% muscle strength recovery 2-3 years.
| Nerve Conduction Study | Onset latency (ms) | Amplitude (mV) | Segment | Velocity (m/s) |
|------------------------|-------------------|----------------|---------|---------------|
| **Motor nerve**        |                   |                |         |               |
| Median                 | Wrist             | 3.3            | 8.2     | Wrist to APB  |
|                        | Elbow             | 6.4            | 8.0     | Elbow to wrist|
| Ulnar                  | Wrist             | 2.8            | 10.4    | Wrist to ADM  |
|                        | Below elbow       | 6.1            | 9.5     | Below elbow to wrist|
|                        | Above elbow       | 8.2            | 9.3     | Above to below elbow|
| **Sensory nerve**      |                   |                |         |               |
| Median                 |                   | 2.3            | 13.6    | Wrist to digit 2|
| Ulnar                  |                   | 2.2            | 13.1    | Wrist to digit 5|
| Radial                 |                   | 1.7            | 30.2    | Wrist to base of digit 1|
| LAC\(^a\)             |                   | 2.8            | 9.0     | Elbow to lateral forearm|
| MAC                    |                   | 2.0            | 18.5    | Elbow to medial forearm|
| **Needle electromyography** |             |                |         |               |
| Muscle                 | Nerve             | Root           | Insertional Activity | Fibs and PSW | MUAP Amp | MUAP Duration | Recruitment Pattern |
| Cervical paraspinals  | Posterior primary rami | C1-T1 | Normal | None | Normal | Normal | Normal |
| Rhomboid major         | Dorsal scapular  | C5             | Inc | 1+ | Inc | Inc | Decreased, Neuropathic |
| Supraspinatus          | Suprascapular    | C5-C6          | Normal | 1+ | Inc | Inc | Decreased, Neuropathic |
| Deltoïd                | Axillary         | C5-C6          | Inc | 1+ | Inc | Inc | Decreased, Neuropathic |
| Biceps brachii         | Musculocutaneous | C5-C6          | Normal | None | Inc | Inc | Decreased, Neuropathic |
| Triceps brachii        | Radial           | C6-C8          | Inc | Inc | Inc | Inc | Decreased, Neuropathic |
| FPL                    | Anterior interosseous | C8-T1 | Normal | None | Normal | Normal | Normal |
| FDS                    | Median            | C7-T1          | Normal | None | Normal | Normal | Normal |
| ECR                    | Radial            | C6-C7          | Inc | 1+ | Inc | Inc | Decreased, Neuropathic |
| APB                    | Median            | C8-T1          | Normal | None | Normal | Normal | Normal |
| FDI                    | Ulnar             | C8-T1          | Normal | None | Normal | Normal | Normal |

**Abbreviations:** APB, abductor pollicis brevis; ADM, abductor digiti minimi; ECR, extensor carpi radialis; FDS, flexor digitorum superficialis; FDI, first dorsal interossei; Fib, fibrillation; FPL, flexor pollicis longus; Inc, increased; LAC, lateral antebrachial cutaneous; MAC, medial antebrachial cutaneous; MUAP, motor unit action potential; PSW, positive sharp wave.

\(^a\)Right-sided LAC study showed onset latency 2.0 ms, amplitude 22.1 μV, and velocity of 50 m/s.
After symptom onset, with ≥70% experiencing residual exercise intolerance and paresis.\textsuperscript{3,4} Anecdotal evidence supports oral prednisone within the first month of symptom onset to decrease painful symptom duration and accelerate recovery.\textsuperscript{4} Treatment is supportive, as there are currently no evidence-based pharmacologic or rehabilitation interventions.\textsuperscript{4}

Approximately 29,585,627 Pfizer-BioNTech COVID-19 vaccine doses have been administered in the United States as of February 19, 2021.\textsuperscript{6} Four INA cases after the Pfizer-BioNTech COVID-19 vaccine have been listed on VAERS\textsuperscript{7} as either “radiculitis brachial” or “brachial plexus injury,” including the presented case. As large-scale COVID-19 vaccinations continue, additional cases of postvaccination INA will likely be reported. Increased clinician awareness of INA after COVID-19 vaccination is essential for proper diagnosis, evaluation, management, and outcome prognostication.

DISCLOSURES
Nicole Diaz-Segarra, Arline Edmond, Courtney Gilbert, Ondrea McKay, Carolyn Kloepping, and Peter Yonclas have nothing to disclose. The case presented was original and used only after written informed consent was obtained from the patient. The adverse event detailed in the manuscript has been reported to the appropriate regulatory agencies.

Nicole Diaz-Segarra MD\textsuperscript{1} 
Arlene Edmond MD\textsuperscript{1} 
Courtney Gilbert MD\textsuperscript{1} 
Ondrea McKay MD\textsuperscript{1} 
Carolyn Kloepping MD\textsuperscript{2} 
Peter Yonclas MD\textsuperscript{1,3}

\textsuperscript{1}Department of Physical Medicine and Rehabilitation, Rutgers-New Jersey Medical School, Newark, New Jersey, USA
\textsuperscript{2}Department of Anesthesia, Rutgers-New Jersey Medical School, Newark, New Jersey, USA
\textsuperscript{3}Department of Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey, USA

REFERENCES
1. Oliver SE, Gargano JW, Marin M, et al. The advisory committee on immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922.
2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N.Engl. J. Med. 2020;383(27):2603-2615.
3. Mitry MA, Collins LK, Kazam JJ, Kaicker S, Kovanlikaya A. Parsonage-turner syndrome associated with SARSCoV2 (COVID-19) infection. Clin Imaging. 2020;72:8-10.
4. Van Alfen N. Clinical and pathophysiological concepts of neuralgic amyotrophy. Nat Rev Neurol. 2011;7(6):315.
5. Shaikh MF, Baqai TJ, Tahir H. Acute brachial neuritis following influenza vaccination. BMJ Case Rep. 2012;2012:bcr2012007673.
6. Centers For Disease Control: COVID-19 Vaccinations in the United States. https://covid.cdc.gov/covid-data-tracker/#vaccinations. Accessed 19 February, 2021.
7. Vaccine Adverse Event Reporting System (VAERS) Database. https://vaers.hhs.gov/data.html. Accessed 19 February, 2021.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Diaz-Segarra N, Edmond A, Gilbert C, McKay O, Kloepping C, Yonclas P. Painless idiopathic neuralgic amyotrophy after COVID-19 vaccination: A case report. PM&R. 2022;14:889–891. https://doi.org/10.1002/pmrj.12619